Jan. 5, 2022 – A CDC advisory sheet contiguous recommended that 12- to 17-year-olds successful the U.S. should get the Pfizer COVID-19 booster changeable 5 months aft a superior bid of vaccinations.
The CDC had already said 16- and 17-year-olds “may” person a Pfizer booster but today’s proposal adds the 12-15 radical and strengthens the “may” to “should” for 16- and 17-year-olds.
The committee voted 13-1 to urge the booster for ages 12-17.
The ballot comes aft the FDA on Monday authorized the Pfizer vaccine booster dose for 12- to 15-year-olds.
The FDA enactment updated the authorization for the Pfizer vaccine, and the bureau besides shortened the recommended clip betwixt a 2nd dose and the booster to 5 months oregon much (from 6 months). A 3rd superior bid dose is besides present authorized for definite immunocompromised children betwixt 5 and 11 years old. Full details are disposable successful an FDA quality release.
The CDC connected Tuesday besides backed the shortened clip framework and a 3rd superior bid dose for immoderate immunocompromised children 5 to 11 years old. But the CDC delayed a determination connected a booster for 12- to 15-year-olds until it heard from its Advisory Committee connected Immunization Practices today.
The determination came arsenic schoolhouse districts nationwide are wrestling with decisions of whether to support schools unfastened oregon revert to a virtual format arsenic cases surge, and arsenic pediatric COVID-19 cases and hospitalizations scope caller highs.